For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Peptide Database

Peptide database

Browse and explore comprehensive, sex-disaggregated peptide profiles.

91 peptides indexed · 82 reviewedASK VERA
24 results in this view
4
4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)
CAS Methionine: 63-68-3; Choline: 62-49-7; L-Carnitine: 541-15-1; Dexpanthenol: 81-13-0

The 4X Blend is a research preparation combining four metabolic cofactors, methionine, choline chloride, carnitine, and dexpanthenol (provitamin B5), in a…

Typical dose
N/A
Route
blend, see ingredients
View ↗
5
5-Amino-1MQ
5-amino-1-methylquinolinium
nnmt-inhibitormetabolicpreclinical

5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT investigated for metabolic and muscle effects.

Typical dose
No established human dose; NNMT inhibition characterized in cell and rodent models only.
Route
oral
D2 of 3 female-tagged
3 studies ↗
8
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)
CAS L-Carnitine: 541-15-1; L-Arginine: 74-79-3; Methionine: 63-68-3; Inositol: 87-89-8; Choline: 62-49-7; B6 (pyridoxine): 65-23-6; B5 (dexpanthenol): 81-13-0; B12: 68-19-9

The 8X Blend is a research preparation combining eight metabolic cofactors, L-carnitine, L-arginine, methionine, inositol, choline, vitamin B6 (pyridoxine),…

Typical dose
N/A
Route
blend, see ingredients
View ↗
A
Adipotide
Prohibitin-TP01
pro-apoptoticanti-obesitypreclinical

Adipotide is a peptidomimetic that targets the blood supply of white fat, causing weight loss in obese animals (including monkeys).

Typical dose
No established human dose; weight loss shown in animal models, with dose-limiting kidney effects noted.
Route
subcutaneous
D2 of 4 female-tagged
4 studies ↗
A
AOD-9604
hGH Fragment 176-191 (modified)
hgh-fragmentlipolysisfailed-trials

AOD-9604 is a modified fragment of human growth hormone (176–191) originally developed as an anti-obesity agent.

Typical dose
Up to ~1 mg/day oral studied in Phase 2 obesity trials; no efficacious dose established.
Route
oral
C3 of 22 female-tagged
22 studies ↗
C
Cagrilintide
AM833
amylin-analoginvestigationalmetabolic

Cagrilintide is a long-acting amylin analog in clinical development for weight management, frequently studied combined with semaglutide (CagriSema).

Typical dose
Investigational once-weekly subcutaneous dosing in trials (literature figures, not advice).
Route
subcutaneous
B18 of 109 female-tagged
109 studies ↗
C
Cagrilintide (2.5mg) / GLP-1 S
CAS Cagrilintide: 1415456-99-3; Semaglutide: 910463-68-2

FOR RESEARCH PURPOSES ONLY.

Typical dose
N/A
Route
blend, see ingredients
View ↗
C
Cagrilintide (5mg) / GLP-1 S
CAS Cagrilintide: 1415456-99-3; Semaglutide: 910463-68-2

<p>FOR RESEARCH PURPOSES ONLY.

Typical dose
N/A
Route
blend, see ingredients
View ↗
C
CCK-8
Cholecystokinin Octapeptide
gut-peptidesatietyapproved-diagnostic

CCK-8 is the active octapeptide of cholecystokinin, a gut hormone central to satiety and digestion.

Typical dose
Sincalide is given by weight-based intravenous infusion for diagnostic gallbladder testing per its approved label.
Route
intravenous
A6,446 of 32,441 female-tagged
32441 studies ↗
H
HGH Fragment 176-191
hGH 176-191
hgh-fragmentlipolysispreclinical

HGH Fragment 176-191 is the unmodified C-terminal lipolytic fragment of human growth hormone.

Typical dose
No established human dose; lipolytic activity described mainly in preclinical and analog (AOD-9604) work.
Route
subcutaneous
D1 of 3 female-tagged
3 studies ↗
I
Irisin
FNDC5 fragment
myokineexerciseendogenous

Irisin is an exercise-induced myokine (cleaved from FNDC5) studied for browning of fat and metabolic and bone effects.

Typical dose
No established human dose; used as a research protein in preclinical (cell and animal) models only.
Route
subcutaneous
D787 of 2,888 female-tagged
2888 studies ↗
L
Linaclotide
Linzess
guanylate-cyclase-c-agonistibs-capproved

Linaclotide (Linzess/Constella) is an FDA-approved guanylate cyclase-C agonist for IBS with constipation and chronic idiopathic constipation, conditions…

Typical dose
72–290 µg once daily by mouth depending on indication, per the approved label.
Route
oral
A106 of 467 female-tagged
467 studies ↗
L
Liraglutide
Victoza
glp-1-agonistfda-approvedmetabolic

Liraglutide is a GLP-1 receptor agonist approved as Victoza (type 2 diabetes) and Saxenda (chronic weight management).

Typical dose
Approved labels use titrated subcutaneous daily dosing (literature figures, not advice).
Route
subcutaneous
A1,339 of 5,517 female-tagged
5517 studies ↗
M
Mazdutide
IBI362
glp-1-glucagondual-agonistobesity

Mazdutide is a GLP-1/glucagon dual-receptor agonist based on oxyntomodulin, developed for obesity and type 2 diabetes.

Typical dose
Up to ~9 mg subcutaneous weekly in late-stage obesity trials; recently approved in China, investigational elsewhere.
Route
subcutaneous
B8 of 46 female-tagged
46 studies ↗
M
MOTS-c
mitochondrial-derived peptide
mitochondrial-derived-peptideampkmetabolic

MOTS-c is a mitochondrial-derived peptide studied in metabolic and exercise-physiology research.

Typical dose
Reported in animal studies only; no established human dose.
Route
subcutaneous
D58 of 304 female-tagged
304 studies ↗
P
Plecanatide
Trulance
guanylate-cyclase-c-agonistconstipationapproved

Plecanatide (Trulance) is an FDA-approved guanylate cyclase-C agonist for chronic idiopathic constipation and IBS with constipation, conditions that are more…

Typical dose
3 mg once daily by mouth per the approved label.
Route
oral
A22 of 125 female-tagged
125 studies ↗
R
Retatrutide
GLP-3 RT
gip-glp1-glucagon-agonistweight-lossinvestigational

Retatrutide is an investigational triple GIP/GLP-1/glucagon receptor agonist in Phase 2 development for obesity.

Typical dose
Investigational; no established dose. Trial doses only.
Route
subcutaneous
B20 of 158 female-tagged
158 studies ↗
S
Secretin
ChiRhoStim (human secretin)
gut-hormoneapproved-diagnosticpancreatic

Secretin is a gut hormone that regulates pancreatic and biliary secretion; its synthetic form is FDA-approved as a diagnostic agent (pancreatic function and…

Typical dose
Weight-based intravenous dosing for the approved diagnostic (secretin stimulation) tests.
Route
intravenous
A1,932 of 7,331 female-tagged
7331 studies ↗
S
Semaglutide
Ozempic
glp-1-agonistweight-lossfda-approved

Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with large trials that enrolled substantial numbers of…

Typical dose
Per approved label; titrated. Reported here for reference, not as advice.
Route
subcutaneous
A1,116 of 5,189 female-tagged
5189 studies ↗
S
SLU-PP-332
ERR pan-agonist
err-agonistexercise-mimeticpreclinical

SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ) studied as an 'exercise mimetic.' The evidence is entirely preclinical…

Typical dose
No established human dose; characterized in cell and rodent models only.
Route
oral
D0 of 10 female-tagged
10 studies ↗
S
Survodutide
BI 456906
glp-1-glucagondual-agonistmash

Survodutide (BI 456906) is a GLP-1/glucagon dual-receptor agonist in Phase 2/3 development for obesity and metabolic dysfunction-associated steatohepatitis…

Typical dose
Doses up to ~6 mg subcutaneous weekly in Phase 2 trials; investigational.
Route
subcutaneous
B10 of 71 female-tagged
71 studies ↗
T
Tesamorelin
Egrifta
ghrh-analogvisceral-fatfda-approved

Tesamorelin is a growth-hormone-releasing hormone analog approved to reduce visceral fat in HIV-associated lipodystrophy.

Typical dose
Per approved label. Reported here for reference, not as advice.
Route
subcutaneous
A32 of 103 female-tagged
103 studies ↗
T
Tesofensine
NS2330
triple-reuptake-inhibitorobesityinvestigational

Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor that produced notable weight loss in Phase 2 obesity trials after failing as a…

Typical dose
0.25–1 mg/day oral studied in Phase 2 obesity trials; investigational.
Route
oral
B12 of 56 female-tagged
56 studies ↗
T
Tirzepatide
Mounjaro
gip-glp1-agonistweight-lossfda-approved

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management.

Typical dose
Per approved label; titrated. Reported here for reference, not as advice.
Route
subcutaneous
A443 of 2,288 female-tagged
2288 studies ↗

About the peptide database

How many peptides are in the database?

The database indexes 91 research peptides, of which 82 have completed a full sex-disaggregated evidence review. The rest carry their research facts while the female-evidence review is written.

How is each peptide's evidence grade decided?

Every compound's A–E grade is derived from published study fields by a fixed, transparent rubric, not an opaque score. Grade A requires human evidence that included female subjects; grade E means anecdotal, in-vitro, or no indexed studies.

What does the female study count tell me?

It shows how many indexed studies included female subjects and, separately, how many reported outcomes by sex. Where no qualifying female study exists, the profile says "unstudied" rather than extrapolating from male data.

Can I search the database by symptom or goal?

Yes. Use the search box to match compound names, aliases, and research tags, or filter by research area such as hormonal, metabolic, skin, or recovery. Vera, the cited AI assistant, can also answer questions across the whole database.